| # | Code | QID |
Subspecialty
|
Topic
|
Complexity
|
Importance
|
Question Count |
|---|---|---|---|---|---|---|---|
| 1 | M1.PY.17.4698 | 108207 | Personality Disorders |
M 3
|
A
|
0
0%
0
|
|
| 2 | M1.OMB.20.4673 | 214219 | Chronic Kidney Disease (CKD) |
M 2
|
A
|
0
0%
0
|
|
| 3 | M1.BC.17.4695 | 107982 | Fat Soluble Vitamins |
M 1
|
A
|
0
0%
0
|
|
| 4 | M1.OMB.4875 | 214775 | Ethical Principles |
M 1
|
A
|
0
0%
0
|
|
| 5 | M1.OMB.4874 | 214529 | Ethical Principles |
M 1
|
A
|
0
0%
0
|
|
| 6 | M1.OMB.1 | 214355 | Ethical Principles |
M 3
|
A
|
0
0%
0
|
|
| 7 | M1.OMB.1 | 214770 | Ethical Principles |
M 1
|
A
|
0
0%
0
|
|
| 8 | M1.OMB.1 | 214605 | Ethical Principles |
M 1
|
A
|
0
0%
0
|
|
| 9 | M1.OMB.20.1 | 213740 | Ethical Principles |
M 3
|
A
|
0
0%
0
|
|
| 10 | M1.OMB.1 | 214645 | Legal Principles |
M 1
|
A
|
0
0%
0
|
|
| 11 | M1.OMB.4771 | 214774 | Legal Principles |
M 1
|
A
|
0
0%
0
|
|
| 12 | M1.OMB.20.4770 | 214203 | Legal Principles |
M 1
|
A
|
0
0%
0
|
|
| 13 | M1.OMB.1 | 214602 | Testing and Screening |
M 1
|
A
|
0
0%
0
|
|
| 14 | M1.OMB.20.4730 | 213799 | Testing and Screening |
A
|
0
0%
0
|
||
| 15 | M1.OMB.4731 | 214561 | Testing and Screening |
M 1
|
A
|
0
0%
0
|
|
| 16 | M1.OMB.4732 | 214850 | Testing and Screening |
M 1
|
A
|
0
0%
0
|
|
| 17 | M1.OMB.20.1 | 214196 | Acute Kidney Injury |
M 2
|
A
|
0
0%
0
|
|
| 18 | M1.CV.15.75 | 106831 | Cardiac Cycle |
M 1
|
A
|
0
0%
0
|
|
| 19 | M1.OMB.4886 | 214347 | Lipid Lowering Drugs |
M 3
|
A
|
0
0%
0
|
|
| 20 | M1.OMB.1 | 214611 | Lipid Lowering Drugs |
M 3
|
A
|
0
0%
0
|
|
| 21 | M1.OMB.1 | 214372 | Lipid Lowering Drugs |
M 3
|
A
|
0
0%
0
|
|
| 22 | M1.OMB.1 | 214959 | Lipid Lowering Drugs |
M 3
|
A
|
0
0%
0
|
|
| 23 | M1.OMB.4887 | 214806 | Observational Studies |
M 1
|
A
|
0
0%
0
|
|
| 24 | M1.OMB.1 | 214713 | Observational Studies |
M 1
|
A
|
0
0%
0
|
|
| 25 | M1.OMB.4885 | 214681 | Observational Studies |
M 1
|
A
|
0
0%
0
|
|
| 26 | M1.OMB.4886 | 214746 | Observational Studies |
M 1
|
A
|
0
0%
0
|
|
| 27 | M1.OMB.1 | 214777 | Observational Studies |
M 1
|
A
|
0
0%
0
|
|
| 28 | M1.OMB.20.4875 | 214229 | Congestive Heart Failure |
M 2
|
A
|
0
0%
0
|
|
| 29 | M1.OMB.1 | 215108 | Congestive Heart Failure |
M 3
|
A
|
0
0%
0
|
|
| 30 | M1.OMB.4876 | 215179 | Congestive Heart Failure |
M 2
|
A
|
0
0%
0
|
|
| 31 | M1.OMB.20.1 | 213781 | Congestive Heart Failure |
M 3
|
A
|
0
0%
0
|
|
| 32 | M1.OMB.1 | 214915 | Modes of Inheritance |
M 1
|
A
|
0
0%
0
|
|
| 33 | M1.OMB.4876 | 214474 | Modes of Inheritance |
M 1
|
A
|
0
0%
0
|
|
| 34 | M1.OMB.1 | 214427 | Modes of Inheritance |
M 2
|
A
|
0
0%
0
|
|
| 35 | M1.OMB.20.4875 | 213879 | Modes of Inheritance |
M 1
|
A
|
0
0%
0
|
|
| 36 | M1.OMB.1 | 214601 | Lysosome |
M 2
|
A
|
0
0%
0
|
|
| 37 | M1.OMB.20.1 | 214271 | Lysosome |
M 2
|
A
|
0
0%
0
|
|
| 38 | M1.OMB.20.1 | 213780 | Lysosome |
M 2
|
A
|
0
0%
0
|
|
| 39 | M1.OMB.1 | 214914 | Myocardial Infarction |
M 1
|
A
|
0
0%
0
|
|
| 40 | M1.OMB.4799 | 214711 | Mycobacterium Tuberculosis |
M 1
|
A
|
0
0%
0
|
|
| 41 | M1.OMB.1 | 214365 | Myocardial Infarction |
M 1
|
A
|
0
0%
0
|
|
| 42 | M1.OMB.4875 | 214454 | Myocardial Infarction |
M 2
|
A
|
0
0%
0
|
|
| 43 | M1.OMB.1 | 214613 | Mycobacterium Tuberculosis |
M 4
|
A
|
0
0%
0
|
|
| 44 | M1.OMB.4888 | 214925 | Statistical Distribution |
M 1
|
A
|
0
0%
0
|
|
| 45 | M1.OMB.1 | 214633 | Statistical Distribution |
M 1
|
A
|
0
0%
0
|
|
| 46 | M1.ST.12.4887 | 214373 | Statistical Distribution |
M 1
|
A
|
0
0%
0
|
|
| 47 | M1.OMB.20.4767 | 214302 | Statistical Measures |
M 1
|
A
|
0
0%
0
|
|
| 48 | M1.OMB.20.1 | 214276 | Cranial Nerves |
M 2
|
A
|
0
0%
0
|
|
| 49 | M1.OMB.4768 | 214930 | Baroreceptors and Chemoreceptors |
M 3
|
A
|
0
0%
0
|
|
| 50 | M1.OMB.4768 | 215112 | Statistical Measures |
M 1
|
A
|
0
0%
0
|
|
| 51 | M1.OMB.20.4767 | 213839 | Baroreceptors and Chemoreceptors |
M 1
|
A
|
0
0%
0
|
|
| 52 | M1.OMB.20.1 | 214199 | Baroreceptors and Chemoreceptors |
M 1
|
A
|
0
0%
0
|
|
| 53 | M1.OMB.1 | 215174 | Baroreceptors and Chemoreceptors |
M 1
|
A
|
0
0%
0
|
|
| 54 | M1.OMB.20.1 | 214193 | Statistical Measures |
M 1
|
A
|
0
0%
0
|
|
| 55 | M1.OMB.4803 | 215200 | Diabetes Drugs |
M 3
|
A
|
0
0%
0
|
|
| 56 | M1.OMB.4802 | 214981 | Diabetes Drugs |
M 1
|
A
|
0
0%
0
|
|
| 57 | M1.OMB.1 | 214773 | Diabetes Drugs |
M 3
|
A
|
0
0%
0
|
|
| 58 | M1.OMB.20.138 | 213869 | Emphysema |
M 2
|
A
|
0
0%
0
|
|
| 59 | M1.OMB.1 | 215130 | Water Soluble Vitamins |
M 1
|
A
|
0
0%
0
|
|
| 60 | M1.OMB.1 | 214598 | Emphysema |
M 1
|
A
|
0
0%
0
|
|
| 61 | M1.OMB.1 | 214889 | Cardiomyopathies |
M 2
|
A
|
0
0%
0
|
|
| 62 | M1.OMB.20.1 | 213887 | Amino Acid Catabolism |
M 1
|
A
|
0
0%
0
|
|
| 63 | M1.OMB.1 | 214982 | Amino Acid Catabolism |
M 2
|
A
|
0
0%
0
|
|
| 64 | M1.OMB.4868 | 214483 | Bias |
M 1
|
A
|
0
0%
0
|
|
| 65 | M1.OMB.20.1 | 213854 | Cardiomyopathies |
M 2
|
A
|
0
0%
0
|
|
| 66 | M1.OMB.4698 | 214697 | Sickle Cell Anemia |
M 1
|
A
|
0
0%
0
|
|
| 67 | M1.OMB.20.4801 | 213892 | Other Eating Disorders |
M 4
|
A
|
0
0%
0
|
|
| 68 | M1.OMB.1 | 214517 | Asthma |
M 2
|
A
|
0
0%
0
|
|
| 69 | M1.OMB.4802 | 214797 | Other Eating Disorders |
M 2
|
A
|
0
0%
0
|
|
| 70 | M1.OMB.1 | 214640 | Germ Layer Derivatives |
M 1
|
A
|
0
0%
0
|
|
| 71 | M1.OMB.20.4802 | 214288 | Germ Layer Derivatives |
M 2
|
A
|
0
0%
0
|
|
| 72 | M1.OMB.4698 | 214215 | Asthma |
M 3
|
A
|
0
0%
0
|
|
| 73 | M1.OMB.4803 | 214950 | Other Eating Disorders |
M 2
|
A
|
0
0%
0
|
|
| 74 | M1.OMB.4819 | 215050 | Ischemic Stroke |
M 3
|
A
|
0
0%
0
|
|
| 75 | M1.OMB.20.1 | 214275 | Valvular Disease |
M 2
|
A
|
0
0%
0
|
|
| 76 | M1.OMB.1 | 213853 | Ischemic Stroke |
M 2
|
A
|
0
0%
0
|
|
| 77 | M1.OMB.4755 | 214939 | Valvular Disease |
M 2
|
A
|
0
0%
0
|
|
| 78 | M1.OMB.1 | 214362 | Poisons and Treatments |
M 2
|
A
|
0
0%
0
|
|
| 79 | M1.OMB.142 | 214524 | Chronic Bronchitis |
M 2
|
A
|
0
0%
0
|
|
| 80 | M1.OMB.4800 | 214810 | Opportunistic Mycoses |
M 2
|
A
|
0
0%
0
|
|
| 81 | M1.OMB.4818 | 214460 | Diabetes Mellitus |
M 2
|
A
|
0
0%
0
|
|
| 82 | M1.OMB.1 | 214441 | Lung Cancer |
M 2
|
A
|
0
0%
0
|
|
| 83 | M1.OMB.1 | 214610 | Chromosomal Diseases |
M 2
|
A
|
0
0%
0
|
|
| 84 | M1.OMB.20.1 | 213883 | Opiates |
M 1
|
A
|
0
0%
0
|
|
| 85 | M1.OMB.1 | 215173 | Drug Reactions and Side Effects |
M 4
|
A
|
0
0%
0
|
|
| 86 | M1.OMB.20.1 | 214278 | Primary Brain Tumors |
M 2
|
A
|
0
0%
0
|
|
| 87 | M1.OMB.4800 | 214551 | Sarcoidosis |
M 1
|
A
|
0
0%
0
|
|
| 88 | M1.OMB.4873 | 214330 | Drug Reactions and Side Effects |
M 2
|
A
|
0
0%
0
|
|
| 89 | M1.OMB.20.4758 | 214220 | Urinary Tract Infection |
M 3
|
A
|
0
0%
0
|
|
| 90 | M1.OMB.20.4874 | 213726 | Primary Brain Tumors |
M 2
|
A
|
0
0%
0
|
|
| 91 | M1.OMB.4759 | 214653 | Urinary Tract Infection |
M 3
|
A
|
0
0%
0
|
|
| 92 | M1.OMB.4874 | 214926 | Drug Reactions and Side Effects |
M 3
|
A
|
0
0%
0
|
|
| 93 | M1.OMB.1 | 214323 | Opiates |
M 2
|
A
|
0
0%
0
|
|
| 94 | M1.OMB.20.1 | 213768 | Graves Disease |
M 2
|
A
|
0
0%
0
|
|
| 95 | M1.OMB.20.1 | 213779 | Opiates |
M 3
|
A
|
0
0%
0
|
|
| 96 | M1.OMB.4755 | 214612 | Atrioventricular (AV) Heart Block |
M 2
|
A
|
0
0%
0
|
|
| 97 | M1.OMB.4771 | 214936 | Eye Movement |
M 2
|
A
|
0
0%
0
|
|
| 98 | M1.OMB.1 | 214735 | GI Embryology |
M 2
|
A
|
0
0%
0
|
|
| 99 | M1.OMB.20.1 | 213882 | Atrioventricular (AV) Heart Block |
M 2
|
A
|
0
0%
0
|
|
| 100 | M1.OMB.4770 | 214721 | Eye Movement |
M 2
|
A
|
0
0%
0
|
|
| 101 | M1.OMB.4885 | 213793 | Pneumoconioses |
M 2
|
A
|
0
0%
0
|
|
| 102 | M1.OMB.4726 | 214893 | Osteoporosis |
M 2
|
A
|
0
0%
0
|
|
| 103 | M1.OMB.20.4754 | 214200 | Antianginal Therapy |
M 3
|
A
|
0
0%
0
|
|
| 104 | M1.OMB.20.4868 | 213891 | Bruton Agammaglobulinemia |
M 2
|
A
|
0
0%
0
|
|
| 105 | M1.OMB.4725 | 214480 | Osteoporosis |
M 2
|
A
|
0
0%
0
|
|
| 106 | M1.OMB.20.1 | 214273 | Fat Soluble Vitamins |
M 2
|
A
|
0
0%
0
|
|
| 107 | M1.OMB.20.4870 | 213798 | Nephrolithiasis |
M 2
|
A
|
0
0%
0
|
|
| 108 | M1.OMB.20.4886 | 214299 | Pneumoconioses |
M 2
|
A
|
0
0%
0
|
|
| 109 | M1.OMB.1 | 214747 | Nephrolithiasis |
M 2
|
A
|
0
0%
0
|
|
| 110 | M1.OMB.1 | 215165 | Antianginal Therapy |
M 3
|
A
|
0
0%
0
|
|
| 111 | M1.OMB.1 | 214972 | Hepatitis B Virus |
M 2
|
A
|
0
0%
0
|
|
| 112 | M1.OMB.20.4801 | 214223 | HIV |
M 2
|
A
|
0
0%
0
|
|
| 113 | M1.OMB.1 | 214908 | Hypersensitivity |
M 1
|
A
|
0
0%
0
|
|
| 114 | M1.OMB.1 | 214582 | Hepatitis B Virus |
M 4
|
A
|
0
0%
0
|
|
| 115 | M1.OMB.6002 | 214990 | Sympathomimetics |
M 2
|
A
|
0
0%
0
|
|
| 116 | M1.OMB.4819 | 215154 | Transplant |
M 1
|
A
|
0
0%
0
|
|
| 117 | M1.OMB.4771 | 215159 | Atherosclerosis |
M 2
|
A
|
0
0%
0
|
|
| 118 | M1.OMB.1 | 215164 | Branchial Apparatus |
M 1
|
A
|
0
0%
0
|
|
| 119 | M1.OMB.1 | 214970 | DNA Repair |
M 1
|
A
|
0
0%
0
|
|
| 120 | M1.OMB.4871 | 214929 | Branchial Apparatus |
M 2
|
A
|
0
0%
0
|
|
| 121 | M1.OMB.1 | 214706 | Innate Immune Response |
M 1
|
A
|
0
0%
0
|
|
| 122 | M1.OMB.1 | 214351 | Innate Immune Response |
M 1
|
A
|
0
0%
0
|
|
| 123 | M1.OMB.1 | 215151 | DNA Repair |
M 1
|
A
|
0
0%
0
|
|
| 124 | M1.OMB.4800 | 214328 | Treponema pallidum / Syphilis |
M 2
|
A
|
0
0%
0
|
|
| 125 | M1.OMB.4889 | 214335 | Rheumatoid Arthritis |
M 3
|
A
|
0
0%
0
|
|
| 126 | M1.OMB.4801 | 214481 | Treponema pallidum / Syphilis |
M 2
|
A
|
0
0%
0
|
|
| 127 | M1.OMB.4875 | 214556 | Renal Artery Stenosis |
M 2
|
A
|
0
0%
0
|
|
| 128 | M1.OMB.96 | 214702 | Crohn Disease |
M 2
|
A
|
0
0%
0
|
|
| 129 | M1.OMB.1 | 214358 | Renal Artery Stenosis |
M 2
|
A
|
0
0%
0
|
|
| 130 | M1.OMB.4890 | 214455 | Rheumatoid Arthritis |
M 2
|
A
|
0
0%
0
|
|
| 131 | M1.OMB.4728 | 214332 | Malignant Bone Tumors |
M 2
|
A
|
0
0%
0
|
|
| 132 | M1.OMB.4709 | 214374 | Coarctation of the Aorta |
M 2
|
A
|
0
0%
0
|
|
| 133 | M1.ST.12.3 | 214375 | Statistical Hypotheses and Error |
M 1
|
A
|
0
0%
0
|
|
| 134 | M1.OMB.97 | 215041 | Crohn Disease |
M 3
|
A
|
0
0%
0
|
|
| 135 | M1.OMB.4873 | 213875 | Neonatal Respiratory Distress Syndrome |
M 2
|
A
|
0
0%
0
|
|
| 136 | M1.OMB.4708 | 214334 | Coarctation of the Aorta |
M 2
|
A
|
0
0%
0
|
|
| 137 | M1.OMB.20.1 | 214180 | Anticoagulants |
M 3
|
A
|
0
0%
0
|
|
| 138 | M1.OMB.20.4662 | 213860 | Population Genetics |
M 1
|
A
|
0
0%
0
|
|
| 139 | M1.OMB.20.1 | 213885 | Glucose Transport |
M 1
|
A
|
0
0%
0
|
|
| 140 | M1.OMB.20.1 | 214279 | Obsessive-Compulsive Disorder |
M 3
|
A
|
0
0%
0
|
|
| 141 | M1.OMB.1 | 215140 | Schizophrenia |
M 2
|
A
|
0
0%
0
|
|
| 142 | M1.OMB.8 | 215163 | Glucose Transport |
M 1
|
A
|
0
0%
0
|
|
| 143 | M1.OMB.1 | 214636 | Glucose Transport |
M 1
|
A
|
0
0%
0
|
|
| 144 | M1.OMB.1 | 214583 | Measures of Association |
M 1
|
A
|
0
0%
0
|
|
| 145 | M1.OMB.20.1 | 213717 | G Protein-Coupled Receptors (GPCR) |
M 1
|
A
|
0
0%
0
|
|
| 146 | M1.OMB.4751 | 214619 | Cirrhosis and Portal Hypertension |
M 2
|
A
|
0
0%
0
|
|
| 147 | M1.OMB.4752 | 215111 | Cirrhosis and Portal Hypertension |
M 1
|
A
|
0
0%
0
|
|
| 148 | M1.OMB.1 | 214515 | Acid-Base Differential Diagnosis |
M 2
|
A
|
0
0%
0
|
|
| 149 | M1.OMB.20.4818 | 213846 | Diabetic Ketoacidosis (DKA) |
M 2
|
A
|
0
0%
0
|
|
| 150 | M1.OMB.1 | 215184 | G Protein-Coupled Receptors (GPCR) |
M 1
|
A
|
0
0%
0
|